electroCore, Inc.
electroCore, Inc. develops and commercializes non-invasive bioelectronic therapies based on vagus nerve stimulation. Its core products include prescription gammaCore devices for headache and related indications, along with wellness-oriented handheld devices sold in the United States, the United Kingdom, and selected international markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueNon-invasive vagus nerve stimulation devices sold for prescribed use, especially in government and UK healthcare channels.
Truvaga handheld products marketed for general wellness and sold through consumer channels and e-commerce.
Consumer-oriented handheld devices positioned for wellness and human performance use.
Sales of nVNS products outside the United States and the United Kingdom through distribution partners.
Customers
The company sells primarily to federal healthcare systems in the United States and to the UK National Health Service, which use gammaCore through prescription and procurement channels. It also serves individual consumers through Truvaga and TAC-STIM, and uses distribution partners to reach selected international markets. The customer base is shaped by reimbursement, procurement portals, and direct-to-consumer e-commerce access.
VA, DoD, MHS and IHS facilities buy gammaCore for covered patients through federal procurement channels.
NHS buyers use prescription gammaCore under funding and catalog arrangements for cluster headache treatment.
Consumers purchase Truvaga and TAC-STIM for general wellness and human performance use.
Partners buy or distribute nVNS products in selected territories outside the U.S. and UK.
Strategy
electroCore is focused on expanding prescription gammaCore within federal healthcare and the UK public system while broadening access through additional reimbursement, cash-pay, and direct-to-consumer channels. It is also extending its product set into wellness and human performance devices and using distribution partners to reach more international markets. The strategy is designed to reduce dependence on any single channel while leveraging the same non-invasive neuromodulation platform.
The VA and related federal systems are the largest revenue source and provide repeat procurement access.
NHS listing and funding support are important for prescription gammaCore adoption in the UK.
Consumer products diversify revenue beyond prescription reimbursement and government procurement.
Selected territories outside the U.S. and UK can extend the platform without building full direct sales coverage.
Geography
Q3/2024The company’s commercial footprint is centered in the United States and the United Kingdom, with the U.S. federal channel and NHS representing the most important markets. It also sells through distribution partners in selected territories outside these core markets. Geography matters because reimbursement, procurement portals, and regulatory clearance differ materially by country and channel.
Share of the revenue the company reports by geography.
Risks
The business depends heavily on a small number of government and public healthcare buyers, so procurement changes, reimbursement decisions, or guidance updates can materially affect sales. It also faces commercialization risk in consumer channels, where e-commerce platform policies, competition, and regulatory classification can disrupt access. As a development-stage medical device company with recurring losses, it remains exposed to financing, covenant, and execution risk as it scales its product mix.
- Financing and covenant constraintsImpact: HighLikelihood: High
The company has recurring losses and debt arrangements can restrict operating flexibility and asset use.
Exposure: Loan and Security Agreement with Avenue
- Customer concentration in federal and UK public healthcare channelsImpact: HighLikelihood: Low
A large share of revenue comes from a few buyers and procurement systems, so contract or policy changes can quickly affect sales.
Exposure - Reimbursement and guidance risk in the UKImpact: High
NICE or NHS changes could alter access, pricing, or funding for gammaCore under the MTFM program.
Exposure: United Kingdom
- E-commerce marketplace dependencyImpact: MediumLikelihood: High
Truvaga sales rely on online marketplaces that can suspend listings or classify products as regulated medical devices.
Exposure: Direct-to-consumer channels
Accounting
Judgemental itemsGovernment contracts, distributor sales and e-commerce sales may recognize revenue at different points in time.
Impact: Quarterly revenue comparability
Management noted gross profit can be affected by changes in useful-life estimates for licensed devices.
Impact: Gross margin and depreciation/amortization
Consumer and marketplace sales can create inventory build or write-down risk if demand or platform access changes.
Impact: Cost of goods sold and working capital
The loan agreement includes covenants and asset liens that may require careful disclosure and classification.
Impact: Liquidity presentation and going-concern assessment
Similar listed companies
Publicly listed companies with a comparable business focus.
Vycor Medical Inc
VYCO · Surgical & Medical Instruments & Apparatus
Electromed, Inc.
ELMD · Electromedical & Electrotherapeutic Apparatus
NovoCure Ltd
NVCR · Surgical & Medical Instruments & Apparatus
NovoCure Ltd develops and commercializes Tumor Treating Fields (TTFields) therapy, a non-invasive cancer treatment delivered through portable medical devices and arrays worn by patients.
IR-Med, Inc.
Electromedical & Electrotherapeutic Apparatus
Inspire Medical Systems, Inc.
INSP · Surgical & Medical Instruments & Apparatus
Inspire Medical Systems develops and commercializes a minimally invasive neurostimulation therapy for obstructive sleep apnea.
Tactile Systems Technology, Inc
TCMD · Surgical & Medical Instruments & Apparatus
Tactile Systems Technology is a U.S.-based medical technology company that develops and sells home-based devices for chronic disease management.
Last updated: 24/09/2026